UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Costimulatory and coinhibitory receptors in anti-tumor immunity

Immunological reviews, 2009-05, Vol.229 (1), p.126-144

2009

Volltextzugriff (PDF)

Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors

Cancer immunology research, 2020-01, Vol.8 (1), p.32-45

2020

Volltextzugriff (PDF)

TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice

The Journal of clinical investigation, 2023-02, Vol.133 (4), p.1-11

2023

Volltextzugriff (PDF)

74 a-TIGIT mAb belrestotug in combination with anti-PD1 induces an immunocompetent tumor microenvironment (TME)

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A84-A84

2023

Volltextzugriff (PDF)

designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library

Proceedings of the National Academy of Sciences - PNAS, 2009-12, Vol.106 (52), p.22211-22216

2009

Volltextzugriff (PDF)

Defining the mode of tumour growth by clonal analysis

Nature (London), 2012-08, Vol.488 (7412), p.527-530

2012

Volltextzugriff (PDF)

Long Live Sox2: Sox2 Lasts a Lifetime

Cell stem cell, 2011-10, Vol.9 (4), p.283-284

2011

Volltextzugriff (PDF)

Deciphering tumor growth by clonal analysis

Critical reviews in oncogenesis, 2014, Vol.19 (5), p.317-325

Driessens, Gregory

2014

Volltextzugriff (PDF)

SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma

Nature (London), 2014-07, Vol.511 (7508), p.246-250

2014

Volltextzugriff (PDF)

Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo

The Journal of experimental medicine, 2012-11, Vol.209 (12), p.2157-2163

2012

Volltextzugriff (PDF)

Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8⁺ T cells

European journal of immunology, 2008-09, Vol.38 (9), p.2438-2450

2008

Volltextzugriff (PDF)

A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours

Nature (London), 2011-10, Vol.478 (7369), p.399-403

2011

Volltextzugriff (PDF)

TIG-007: Study of EOS884448/GSK4428859A Alone, and in Combination with Iberdomide with or without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.2745-2745

2021

Volltextzugriff (PDF)

Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL

Blood, 2019-11, Vol.134 (Supplement_1), p.391-391

2019

Volltextzugriff (PDF)

Abstract 3249: a-TIGIT mediates antitumor activity through multiple mechanisms of action involving activation of intratumor effector T cells and depletion of regulatory T cells

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3249-3249

2019

Volltextzugriff (PDF)

The Combination of Anti-Tigit and Lenalidomide Promotes Synergistic Myeloma-Specific Immunity after ASCT

Blood, 2021-11, Vol.138 (Supplement 1), p.328-328

2021

Volltextzugriff (PDF)

Highly successful therapeutic vaccinations combining dendritic cells and tumor cells secreting granulocyte macrophage colony-stimulating factor

Cancer research (Chicago, Ill.), 2004-11, Vol.64 (22), p.8435-8442

2004

Volltextzugriff (PDF)

Abstract 3240: EOS884448, a high affinity fully human antibody directed against TIGIT, mediates in vitro anti-tumor activity through multiples mechanisms of action involving activation of intratumor effector cells and depletion of regulatory T cells

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3240-3240

2019

Volltextzugriff (PDF)

Abstract 3161: Preparation of aclinical trial with a-TIGIT antagonist antibody EOS884448, which demonstrates potent preclinical activity and safe toxicology profile

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3161-3161

2020

Volltextzugriff (PDF)

Abstract CT118: Preliminary data from Phase I first-in-human study of EOS884448, a novel potent anti-TIGIT antibody, monotherapy shows favorable tolerability profile and early signsof clinical activity in immune-resistant advanced cancers

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT118-CT118

2021

Volltextzugriff (PDF)

Abstract 3261: EOS100850, a non-brain penetrant highly selective A2Areceptor antagonist, uniquely maintains high potency within the adenosine rich tumor microenvironment

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3261-3261

2019

Volltextzugriff (PDF)

Abstract 4147: EOS100850, an A2Areceptor antagonist with prolonged pharmacodynamic activity, mediates the generation ofspecific durable immune responses in a murine breast cancer model

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4147-4147

2019

Volltextzugriff (PDF)

β-catenin does not regulate memory T cell phenotype

Nature medicine, 2010-05, Vol.16 (5), p.513-514

2010

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(49)
Buchkapitel
(1)

Sprache

Englisch
(50)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Costimulatory and coinhibitory receptors in anti-tumor immunity

Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors

TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

74 a-TIGIT mAb belrestotug in combination with anti-PD1 induces an immunocompetent tumor microenvironment (TME)

designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library

Defining the mode of tumour growth by clonal analysis

Long Live Sox2: Sox2 Lasts a Lifetime

Deciphering tumor growth by clonal analysis

SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma

Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo

Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8⁺ T cells

A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours

TIG-007: Study of EOS884448/GSK4428859A Alone, and in Combination with Iberdomide with or without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma

Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL

Abstract 3249: a-TIGIT mediates antitumor activity through multiple mechanisms of action involving activation of intratumor effector T cells and depletion of regulatory T cells

The Combination of Anti-Tigit and Lenalidomide Promotes Synergistic Myeloma-Specific Immunity after ASCT

Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies

Highly successful therapeutic vaccinations combining dendritic cells and tumor cells secreting granulocyte macrophage colony-stimulating factor

Abstract 3240: EOS884448, a high affinity fully human antibody directed against TIGIT, mediates in vitro anti-tumor activity through multiples mechanisms of action involving activation of intratumor effector cells and depletion of regulatory T cells

Abstract 3161: Preparation of aclinical trial with a-TIGIT antagonist antibody EOS884448, which demonstrates potent preclinical activity and safe toxicology profile

Abstract CT118: Preliminary data from Phase I first-in-human study of EOS884448, a novel potent anti-TIGIT antibody, monotherapy shows favorable tolerability profile and early signsof clinical activity in immune-resistant advanced cancers

Abstract 3261: EOS100850, a non-brain penetrant highly selective A2Areceptor antagonist, uniquely maintains high potency within the adenosine rich tumor microenvironment

Abstract 4147: EOS100850, an A2Areceptor antagonist with prolonged pharmacodynamic activity, mediates the generation ofspecific durable immune responses in a murine breast cancer model

β-catenin does not regulate memory T cell phenotype

Suchergebnisse filtern